Shanghai Fosun Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has an Asset Resilience Ratio of 1.81% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Shanghai Fosun Pharmaceutical Group Co L strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Shanghai Fosun Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Fosun Pharmaceutical Group Co L balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Fosun Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600196 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.23 Billion | 1.81% |
| Total Liquid Assets | CN¥2.23 Billion | 1.81% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Fosun Pharmaceutical Group Co Ltd maintains only 1.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Fosun Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Fosun Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Fosun Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.97% | CN¥5.99 Billion ≈ $875.80 Million |
CN¥120.47 Billion ≈ $17.63 Billion |
+2.76pp |
| 2024-12-31 | 2.21% | CN¥2.60 Billion ≈ $379.88 Million |
CN¥117.46 Billion ≈ $17.19 Billion |
+0.55pp |
| 2023-12-31 | 1.66% | CN¥1.89 Billion ≈ $276.35 Million |
CN¥113.47 Billion ≈ $16.60 Billion |
+0.80pp |
| 2022-12-31 | 0.87% | CN¥928.53 Million ≈ $135.87 Million |
CN¥107.16 Billion ≈ $15.68 Billion |
-3.68pp |
| 2021-12-31 | 4.55% | CN¥4.24 Billion ≈ $620.60 Million |
CN¥93.29 Billion ≈ $13.65 Billion |
+2.19pp |
| 2020-12-31 | 2.35% | CN¥1.97 Billion ≈ $288.29 Million |
CN¥83.69 Billion ≈ $12.25 Billion |
+1.75pp |
| 2019-12-31 | 0.60% | CN¥456.65 Million ≈ $66.82 Million |
CN¥76.12 Billion ≈ $11.14 Billion |
-0.27pp |
| 2018-12-31 | 0.87% | CN¥616.12 Million ≈ $90.16 Million |
CN¥70.55 Billion ≈ $10.32 Billion |
+0.52pp |
| 2017-12-31 | 0.35% | CN¥219.33 Million ≈ $32.09 Million |
CN¥61.97 Billion ≈ $9.07 Billion |
+0.24pp |
| 2016-12-31 | 0.11% | CN¥48.49 Million ≈ $7.10 Million |
CN¥43.77 Billion ≈ $6.40 Billion |
+0.02pp |
| 2015-12-31 | 0.09% | CN¥33.75 Million ≈ $4.94 Million |
CN¥38.20 Billion ≈ $5.59 Billion |
-0.01pp |
| 2014-12-31 | 0.10% | CN¥33.77 Million ≈ $4.94 Million |
CN¥35.34 Billion ≈ $5.17 Billion |
-0.05pp |
| 2013-12-31 | 0.15% | CN¥44.20 Million ≈ $6.47 Million |
CN¥29.48 Billion ≈ $4.31 Billion |
-0.73pp |
| 2012-12-31 | 0.88% | CN¥224.83 Million ≈ $32.90 Million |
CN¥25.51 Billion ≈ $3.73 Billion |
-0.16pp |
| 2011-12-31 | 1.04% | CN¥231.32 Million ≈ $33.85 Million |
CN¥22.29 Billion ≈ $3.26 Billion |
-0.26pp |
| 2010-12-31 | 1.30% | CN¥218.76 Million ≈ $32.01 Million |
CN¥16.82 Billion ≈ $2.46 Billion |
+1.20pp |
| 2009-12-31 | 0.10% | CN¥11.70 Million ≈ $1.71 Million |
CN¥11.53 Billion ≈ $1.69 Billion |
+0.10pp |
| 2008-12-31 | 0.00% | CN¥94.32K ≈ $13.80K |
CN¥7.54 Billion ≈ $1.10 Billion |
-0.08pp |
| 2007-12-31 | 0.08% | CN¥5.84 Million ≈ $855.13K |
CN¥7.43 Billion ≈ $1.09 Billion |
+0.05pp |
| 2006-12-31 | 0.03% | CN¥2.11 Million ≈ $309.12K |
CN¥6.63 Billion ≈ $970.75 Million |
-0.07pp |
| 2004-12-31 | 0.10% | CN¥5.20 Million ≈ $760.92K |
CN¥5.17 Billion ≈ $756.61 Million |
+0.10pp |
| 2003-12-31 | 0.00% | CN¥200.00K ≈ $29.27K |
CN¥4.22 Billion ≈ $617.35 Million |
-9.08pp |
| 2002-12-31 | 9.09% | CN¥285.35 Million ≈ $41.76 Million |
CN¥3.14 Billion ≈ $459.42 Million |
+9.05pp |
| 2001-12-31 | 0.04% | CN¥871.98K ≈ $127.60K |
CN¥2.21 Billion ≈ $323.00 Million |
-- |
About Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more